An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Buparlisib (Primary) ; Sonidegib (Primary)
- Indications Basal cell cancer; Basal cell nevus syndrome
- Focus Therapeutic Use
- 24 Apr 2017 Planned End Date changed from 31 Dec 2017 to 1 Jun 2017.
- 13 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2015 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2017, as reported by ClinicalTrials.gov.